Announces top-line results of the PIF study and Low dose PK study for SPARC DPI
Sun Pharma Advanced Research Company provided update on its breath activated device SPARC DPI.SPARC DPI is a pre-metered, 60 dose, breath activated device containing Salmeterol - Fluticasone. SPARC DPI uses half the dose of the both Salmeterol and Fluticasone compared to Seretide Accuhaler.
The Company announced the top-line results of the PIF study and Low dose PK study for SPARC DPI.
Anil Raghavan, CEO, SPARC said that the results confirms that the device is highly efficient and consistent in delivering more drug to the lungs and suitable for all classes of patients. The Company will consult the regulatory agencies in Europe to understand the potential path forward for SPARC DPI.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app